Skip to main content
SpringerLink
Log in

Cellular vaccine therapies for cancer

  • Chapter
Biological and Hormonal Therapies of Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 94))

Abstract

The presence of functionally specific tumor-associated antigens was first convincingly demonstrated by Prehn and Main [1]. These investigators immunized syngeneic mice with a chemically induced sarcoma using a technique whereby the transplanted tumor was allowed to grow but was excised before it killed the host. These now surgically cured mice were able to reject a subsequent transplant of the same tumor yet accepted a skin graft from a mouse of the same strain as that in which the tumor had arisen. This experiment provided a scientific foundation for the pursuit of active specific immunization as a cancer treatment (i.e., antigens existed on tumor cells that could be targeted to effect tumor rejection) as well as a caution (i.e., tumors can grow progressively in the presence of concommitant immunity) that until recently seems to have gone unnoticed. Investigators have narrowly focused on improving the immunogenicity of their vaccines and are only now coming to recognize the emerging evidence that human tumors can and do grow in the presence of an immune response.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Prehn RT, Main JM. 1957. Immunity to methylcholanthrene induced sarcomas. J Natl Cancer Inst 18:769–778.

    PubMed  CAS  Google Scholar 

  2. Ikonopisov RL, Lewis MG, Hunter-Craig ID, et al. 1970. Autoimmunization with irradiated tumor cells in human malignant melanoma. Br Med J 2:752–754.

    Article  PubMed  CAS  Google Scholar 

  3. Krementz ET, Samuels MS, Wallace JH. 1971. Clinical experience in the immunotherapy of cancer. Surg Gynecol Obstet 133:209–217.

    PubMed  CAS  Google Scholar 

  4. Currie GA, Lejeune F, Hamilton-Fairley G. 1971. Immunization with irradiated tumor cells and specific lymphocyte cytotoxicity in malignant melanoma. Br Med J 2:305–310.

    Article  PubMed  CAS  Google Scholar 

  5. McCarthy WH, Cotton G, Carlton A, et al. 1973. Immunotherapy of malignant melanoma. A clinical trial. Cancer 32:97–103.

    Article  PubMed  CAS  Google Scholar 

  6. Ahn SS, Irie RF, Weisenburger TH, et al. 1982. Humoral immune response to intralymphatic immunotherapy for disseminated melanoma: correlation with clinical response. Surgery 92:362–367.

    PubMed  CAS  Google Scholar 

  7. Gerner FR, Moore GE. 1976. Feasibility study of immunotherapy in patients with solid tumors. Cancer 38:131–143.

    Article  PubMed  CAS  Google Scholar 

  8. Laucius JF, Bodurtha AJ, Mastrangelo MJ, et al. 1977. A phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma. Cancer 40:2091–2093.

    Article  PubMed  CAS  Google Scholar 

  9. Morton DL, Foshag LJ, Hoon DSB, et al. 1992. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216:463–482.

    Article  PubMed  CAS  Google Scholar 

  10. Berd D, Maguire HC Jr, Mastrangelo MJ. 1986. Induction of cell mediate immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 46:2572–2577.

    PubMed  CAS  Google Scholar 

  11. Berd D, Maguire HC Jr, McCue P, Mastrangelo MJ. 1990. Treatment of metastatic melanoma with an autologous tumor cell vaccine: clinical and immunological results in 64 patients. J Clin Oncol 8:1858–1867.

    PubMed  CAS  Google Scholar 

  12. Mitchell MS. 1995. Active specific immunotherapy of melanoma. Br Med Bull 51:631–646.

    PubMed  CAS  Google Scholar 

  13. Mitchison NA. 1970. Immunologic approach to cancer. Transplant Proc 11:92–103.

    Google Scholar 

  14. Galili ND, Naor B, Asjo B, Klein G. 1976. Induction of immune responsiveness in a genetically low-responsive tumor-host combination by chemical modification of the immunogen. Eur J Immunol 6:473–476.

    Article  PubMed  CAS  Google Scholar 

  15. Livington PO, Albino AP, Chung JJ, et al. 1985. Serological responses of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells. Cancer 55:713–720.

    Article  Google Scholar 

  16. Wallack MK, Steplewski Z, Koprowski H, et al. 1977. A new approach in specific active immunotherapy. Cancer 39:560–564.

    Article  PubMed  CAS  Google Scholar 

  17. Murray DR, Cassel W, Torbin A, et al. 1977. Viral oncolysates in the management of malignant melanoma. Cancer 40:680–686.

    Article  PubMed  CAS  Google Scholar 

  18. Czajkowski NP, Rosenblatt M, Wolf PL, Vazquez J. 1967. A new method of active immunization to autologous human tumor tissue. Lancet 2:905–909.

    Article  PubMed  Google Scholar 

  19. Berd D, Maguire HC Jr, Mastrangelo MJ. 1993. Treatment of human melanoma with haptenmodified autologous vaccine. Ann NY Acad Sci 690:147–152.

    Article  PubMed  CAS  Google Scholar 

  20. Lattime EC, Mastrangelo MJ, Berd D. 1995. Expression of cytokine mRNA in human melanoma cells. Cancer Immunol Immunother 41:151–156.

    Article  PubMed  CAS  Google Scholar 

  21. McCune CS, Schapira DV, Henshaw EC. 1981. Specific immunotherapy of advanced renal carcinoma: evidence for the polyclonality of metastases. Cancer 47:1984–1987.

    Article  PubMed  CAS  Google Scholar 

  22. Rauschmeier HA. 1988. Immunotherapy of metastatic renal cancer. Semin Surg Oncol 4:169–173.

    Article  PubMed  CAS  Google Scholar 

  23. Adler A, Gillon G, Lurie H, et al. 1987. Active specific immunotherapy of renal cell carcinoma patients: a prospective randomized study of hormono-immuno-versus hormonotherapy. Preliminary report of immunological and clinical aspects. J Biol Respir Mod 6:610–624.

    CAS  Google Scholar 

  24. Sahasrabudhe DM, de Kernion JB, Pontes JE, et al. 1986. Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J Biol Respir Med 5:581–594.

    Article  Google Scholar 

  25. Elias EG, Tomazic VJ, Buda BS. 1992. Adjuvant immunotherapy in melanoma: a new approach. J Surg Oncol 50:144–148.

    Article  PubMed  CAS  Google Scholar 

  26. Hedley DW, McElwain TJ, Currie GA. 1977. Tumor regression and survival of patients with disseminated malignant melanoma treated with chemotherapy and specific active immunotherapy. Eur J Cancer 13:1169–1173.

    PubMed  CAS  Google Scholar 

  27. Mc Illmurray MB, Embleton MJ, Reeves WB, et al. 1977. Controlled trial of active immunotherapy in management of stage IIB malignant melanoma. Br Med J 1:540–542.

    Article  Google Scholar 

  28. Mc Illmurray MB, Reeves WG, Langman MJS, et al. 1978. Active immunotherapy in malignant melanoma (letter). Br Med J 1:579.

    Article  Google Scholar 

  29. Hedley DW, McElwain TJ, Currie GA. 1978. Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIB malignant melanoma and may promote early recurrence. Br J Cancer 37:491–496.

    Article  PubMed  CAS  Google Scholar 

  30. Morton DL, Holmes EC, Eilber FR, et al. 1982. Adjuvant immunotherapy: results of a randomized trial in patients with lymph node metastases. In Terry WD, Rosenberg SA, eds. Immunotherapy of Human Cancer. New York: Elsevier North Holland, pp 245–249.

    Google Scholar 

  31. Morton DL. 1986. Adjuvant immunotherapy of malignant melanoma: status of clinical trials at UCLA. Int J Immunother 2:31–36.

    Google Scholar 

  32. Aranha GV, McKhann CF, Grage TB, et al. 1979. Adjuvant immunotherapy of malignant melanoma. Cancer 43:1297–1303.

    Article  PubMed  CAS  Google Scholar 

  33. Terry WE, Hodes RJ, Rosenberg SA, et al. 1982. Treatment of stage I and II malignant melanoma with adjuvant immunotherapy or chemotherapy: preliminary analysis of a prospective randomized trial. In Terry WD, Rosenberg SA, eds. Immunotherapy of Human Cancer. New York: Elsevier North Holland, pp 252–257.

    Google Scholar 

  34. Cassel WA, Murray DR, Phillips HS. 1983. A phase II study of the post surgical management of stage Il melanoma with a Newcastle disease virus oncolysate. Cancer 52:856–860.

    Article  PubMed  CAS  Google Scholar 

  35. Hersey P, Coates A, McCarthy WH. 1993. Active immuotherapy following surgical removal of high risk melanoma. Present status and future prospects (abstract). Proc Soc Biol Ther 8:24.

    Google Scholar 

  36. Wallack MK, Sivanandham M, Balch CM, et al. 1995. A phase III randomized, double-blind, multi-institutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 75:34–42.

    Article  PubMed  CAS  Google Scholar 

  37. Berd D, Maguire HC, Nathan FE, Schuchter LM, Bloome E, Mastrangelo MJ. 1996. Autologous DNP-modified vaccine as post surgical adjuvant treatment of stages III and IV melanoma (abstract). Proc Am Soc Clin Oncol 15:554.

    Google Scholar 

  38. Galligioni E, Quaia M, Merlo A, et al. 1996. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin. Cancer 77:2560–2566.

    Article  PubMed  CAS  Google Scholar 

  39. Hoover HC Jr, Surdyke MG, Dangel RB, et al. 1985. Prospectively randomized trial of adjuvant active specific immunotherapy for human colorectal cancer. Cancer 55:1236–1243.

    Article  PubMed  Google Scholar 

  40. Hoover HC Jr, Brandhorst JS, Peters LC, et al. 1993. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5 year median follow up of a phase III prospectively randomized trial. J Clin Oncol 11:390–399.

    PubMed  Google Scholar 

  41. Harris J, Ryan L, Adams G, et al. 1993. Results of the ECOG trial of autologous colon cancer vaccine (abstract). J Immunother 14:358.

    Article  Google Scholar 

  42. Harris J, Ryan L, Adams G, et al. 1994. Survival and relapse in adjuvant autologous tumor vaccine therapy for Dukes B and C colon cancer (abstract). Proc Am Soc Clin Oncol 13:294.

    Google Scholar 

  43. Jessup JM, McBride CM, Ames FC, et al. 1986. Active specific immuotherapy of Dukes B2 and C colorectal carcinoma: comparison of two doses of the vaccine. Cancer Immunol Immunother 3:233–239.

    Google Scholar 

  44. Schulof RS, Mai D, Nelson MA, et al. 1988. Active specific immunotherapy with an autologous tumor cell vaccine in patients with resected non-small cell lung cancer. Mol Biother 1:30–36.

    PubMed  CAS  Google Scholar 

  45. Perlin E, Oldham RK, Weese JL, et al. 1980. Carcinoma of the lung: immunotherapy with intradermal BCG and allogeneic tumor cells. Int J Radiat Oncol Biol Phys 6:1033–1039.

    Article  PubMed  CAS  Google Scholar 

  46. Maguire HC Jr, Guidotti MB, Weiner WP. 1989. Local murine recombinant interferon heightens the acquisition of allergic contact dermatitis in the mouse. Int Arch Allergy 88:345–347.

    Article  PubMed  Google Scholar 

  47. Tepper RI, Pattengale PK, Leder P. 1989. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57:503–512.

    Article  PubMed  CAS  Google Scholar 

  48. Golumbek PT, Lazenby AJ, Levitsky HI, et al. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713–716.

    Article  PubMed  CAS  Google Scholar 

  49. Rosenberg SA. 1992. The immunotherapy and gene therapy of cancer. J Clin Oncol 10:180–199.

    PubMed  CAS  Google Scholar 

  50. Rosenberg SA, Anderson WF, Blaese RM, et al. 1992. Immunization of cancer patients using autologous cancer cells modified by the insertion of the gene for interleukin-2. Hum Gene Ther 3:75–90.

    Article  Google Scholar 

  51. Jaffee EM, Marshall F, Weber C, et al. 1996. Bioactivity of a human GM-CSF tumor vaccine for the treatment of metastatic renal cell carcinoma (abstract). Proc Am Soc Clin Oncol 15:237.

    Google Scholar 

  52. Lotze MT, Rubin JT. 1994. Gene therapy of cancer: a pilot study of IL-4 gene modified fibroblasts with autologous tumor to elicit an immune response. Hum Gene Ther 5:41–55.

    Article  PubMed  CAS  Google Scholar 

  53. Leong SPL, Enders-Zohr P, Zhou YM, et al. 1996. Active specific immunotherapy with GM-CSF as an adjuvant to autologous melanoma vaccine in metastatic melanoma (abstract). Proc Am Soc Clin Oncol 15:437.

    Google Scholar 

  54. Mastrangelo MJ, Maguire HC Jr, McCue P, et al. 1995. A pilot study demonstrating the feasibility of using intratumoral vaccinia injections as a vector for gene transfer. Vaccine Res 4:58–69.

    Google Scholar 

  55. Stopeck AT, Hersh EM, Akopriaye T, et al. 1995. Phase I study of immunotherapy of malignant melanoma by direct gene transfer of an allogeneic histocompatibility antigen HLAB7 (abstract). Proc Am Soc Clin Oncol 14:227.

    Google Scholar 

  56. Bohm M, Luger TA. 1996. Melanoma-derived cytokines. In Maio M, ed. Immunology of Human Melanoma. Amsterdam: IOS Press, pp 55–69.

    Google Scholar 

  57. Nabioullin R, Sone S, Mizuno K, et al. 1994. Interleukin-10 is a potent inhibitor of tumor cytotoxicity by human monocytes and alveolar macrophages. J Leuk Biol 55:437–440.

    CAS  Google Scholar 

  58. Sato T, McCue P, Masuoka K, et al. 1996. Interleukin-10 production by human melanoma. Clin Cancer Res 2:1383–1390

    PubMed  CAS  Google Scholar 

  59. Chen Q, Daniel V, Maher DW, Hersey P. 1994. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 56:755–760.

    Article  PubMed  CAS  Google Scholar 

  60. VanBelle P, Rodeck U, Nuamah I, et al. 1996. Melanoma-associated expression of transforming growth factor-beta isoforms. Am J Pathol 148:1887–1894.

    CAS  Google Scholar 

Download references

Authors
  1. Michael J. Mastrangelo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takami Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edmund C. Lattime
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Henry C. Maguire Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David Berd
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Lucille Parker Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA

    Kenneth A. Foon M.D.

  2. College of Medicine, Vermont Cancer Center, University of Vermont, Burlington, Vermont, USA

    Hyman B. Muss M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media New York

About this chapter

Cite this chapter

Mastrangelo, M.J., Sato, T., Lattime, E.C., Maguire, H.C., Berd, D. (1998). Cellular vaccine therapies for cancer. In: Foon, K.A., Muss, H.B. (eds) Biological and Hormonal Therapies of Cancer. Cancer Treatment and Research, vol 94. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-6189-7_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-6189-7_3

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7837-2

  • Online ISBN: 978-1-4615-6189-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation